J&J (JNJ) Q1 Earnings Beat Estimates, Pharma Sales Slow Down

by Zacks Equity Research Published on April 18,2017

Johnson & Johnson (JNJ) reported mixed first quarter results, with earnings beating expectations while sales missing the same.

• PFE Quick QuotePFENegative Net Change
• JNJ Quick QuoteJNJNo Net Change
• MRK Quick QuoteMRKNegative Net Change
• ALIOF Quick QuoteALIOFNo Net Change

J&J (JNJ) Beats on Q1 Earnings, Sales Miss Again

by Zacks Equity Research Published on April 18,2017

JNJ beat on first quarter earnings - the company reported EPS of $1.83 while our consensus called for EPS of $1.77.

• JNJ Quick QuoteJNJNo Net Change

5 Hot Earnings Charts to Start the Week

by Tracey Ryniec Published on April 17,2017

Earnings season is here and these companies have some of the best track records on Wall Street.

• NFLX Quick QuoteNFLXPositive Net Change
• JNJ Quick QuoteJNJNo Net Change

5 Major Drug Stocks Likely to Beat Q1 Earnings Estimates

by Zacks Equity Research Published on April 17,2017

2017 is expected to be a strong year for drug stocks.

• BMY Quick QuoteBMYPositive Net Change
• LLY Quick QuoteLLYPositive Net Change
• JNJ Quick QuoteJNJNo Net Change
• AMGN Quick QuoteAMGNNegative Net Change

Why Juno Therapeutics' Stock Tumbled in the Past One Year

by Zacks Equity Research Published on April 13,2017

Juno Therapeutics, Inc.'s (JUNO) stock has significantly underperformed Zacks classified Medical-Biomed/Genetics industry in the past one year.

• NVS Quick QuoteNVSNegative Net Change
• JNJ Quick QuoteJNJNo Net Change
• GSK Quick QuoteGSKPositive Net Change
• JUNO Quick QuoteJUNOPositive Net Change

Should You Sell Johnson & Johnson (JNJ) Before Earnings?

by Zacks Equity Research Published on April 13,2017

Johnson & Johnson (JNJ) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.

• JNJ Quick QuoteJNJNo Net Change

Inovio's Ebola Vaccine Positive in Expanded Phase I Study

by Zacks Equity Research Published on April 12,2017

Inovio Pharmaceuticals, Inc. (INO) recently reported positive preliminary results from the expanded stage of its phase I study, EBOV-001.

• JNJ Quick QuoteJNJNo Net Change
• GSK Quick QuoteGSKPositive Net Change
• MRK Quick QuoteMRKNegative Net Change

Geron Stock Rises after Positive Interim Update on Imetelstat

by Zacks Equity Research Published on April 11,2017

Shares of Geron Corporation (GERN) increased almost 20% on Monday after it provided a positive update on two late-stage studies for imetelstat, its lead pipeline candidate.

• RHHBY Quick QuoteRHHBYPositive Net Change
• SNY Quick QuoteSNYNegative Net Change
• JNJ Quick QuoteJNJNo Net Change
• GERN Quick QuoteGERNNegative Net Change

Merck's Bid to Add Cardiovascular Data on Januvia Label Fails

by Zacks Equity Research Published on April 10,2017

Merck announced that the FDA has denied approval to include cardiovascular outcomes data on the labels of its diabetes drug, Januvia (sitagliptin) and other medicines containing Januvia.

• LLY Quick QuoteLLYPositive Net Change
• NVO Quick QuoteNVOPositive Net Change
• JNJ Quick QuoteJNJNo Net Change

5 Drug Stocks for Your Portfolio this World Health Day

by Arpita Dutt Published on April 07,2017

With "Depression: let's talk" being this year's World Health Day campaign slogan, here's a look at 5 companies developing treatments for various types of depression.

• AGN Quick QuoteAGNPositive Net Change
• JNJ Quick QuoteJNJNo Net Change
• ALKS Quick QuoteALKSPositive Net Change
• SAGE Quick QuoteSAGENo Net Change

AbbVie/J&J's Imbruvica Label Expansion Filing Accepted by FDA

by Zacks Equity Research Published on April 05,2017

AbbVie Inc. (ABBV) and partner Janssen, Johnson & Johnson's (JNJ) pharmaceuticals subsidiary, announced that a supplemental new drug application (sNDA) for their cancer drug Imbruvica has been accepted for review by the FDA.

• RHHBY Quick QuoteRHHBYPositive Net Change
• LLY Quick QuoteLLYPositive Net Change
• JNJ Quick QuoteJNJNo Net Change
• ABBV Quick QuoteABBVNegative Net Change

Pfizer's Arthritis Drug Xeljanz Gets Marketing Nod in Europe

by Zacks Equity Research Published on March 28,2017

Pfizer, Inc.'s (PFE) rheumatoid arthritis (RA) drug, Xeljanz has received marketing approval in Europe.

• PFE Quick QuotePFENegative Net Change
• JNJ Quick QuoteJNJNo Net Change
• ABBV Quick QuoteABBVNegative Net Change
• AMGN Quick QuoteAMGNNegative Net Change

J&J (JNJ) Anaemia Drug Marketing Label Expanded in Europe

by Zacks Equity Research Published on March 27,2017

Johnson & Johnson (JNJ) announced that the French health authority has granted approval to expand the label of Eprex to include treatment of symptomatic anaemia in patients with low or intermediate risk myelodysplastic syndromes (MDS).

• NVS Quick QuoteNVSNegative Net Change
• JNJ Quick QuoteJNJNo Net Change
• GSK Quick QuoteGSKPositive Net Change
• AMGN Quick QuoteAMGNNegative Net Change

Catalyst Pharma (CPRX) Focused on U.S. Approval for Firdapse

by Zacks Equity Research Published on March 23,2017

We issued an updated research report on Catalyst Pharmaceuticals, Inc. (CPRX) on Mar 22.

• PFE Quick QuotePFENegative Net Change
• JNJ Quick QuoteJNJNo Net Change
• BMRN Quick QuoteBMRNNegative Net Change
• CPRX Quick QuoteCPRXNegative Net Change

AT&T & Verizon Suspend Marketing Advertisements from YouTube

by Zacks Equity Research Published on March 23,2017

AT&T Inc. (T) and Verizon Communications Inc. (VZ) have decided to suspend their marketing campaign on Google's YouTube site.

• JNJ Quick QuoteJNJNo Net Change
• GOOGL Quick QuoteGOOGLPositive Net Change

5 Excellent ETFs for Your IRA

by Neena Mishra Published on March 20,2017

Low-cost, diversified ETFs are excellent investment vehicles to build retirement wealth.

• JNJ Quick QuoteJNJNo Net Change
• AAPL Quick QuoteAAPLNegative Net Change
• MSFT Quick QuoteMSFTNegative Net Change
• GSLC Quick QuoteGSLCPositive Net Change

Pharma Stock Roundup: AstraZeneca's Lynparza Impresses in Study, Merck Drug Label Expanded

by Arpita Dutt Published on March 17,2017

Regulatory and pipeline updates from companies like AstraZeneca (AZN) and Merck were in focus this week.

• AZN Quick QuoteAZNPositive Net Change
• AGN Quick QuoteAGNPositive Net Change
• JNJ Quick QuoteJNJNo Net Change

Pfizer's Arthritis Drug Xeljanz Gets Marketing Nod in China

by Zacks Equity Research Published on March 16,2017

Pfizer, Inc.'s (PFE) rheumatoid arthritis (RA) drug, Xeljanz (5 mg taken twice daily) has received marketing approval in China to be used in combination with methotrexate

• PFE Quick QuotePFENegative Net Change
• JNJ Quick QuoteJNJNo Net Change
• AMGN Quick QuoteAMGNNegative Net Change
• ABBV Quick QuoteABBVNegative Net Change

Large Cap ETF (IVV) Tops $100 billion in AUM

by Sweta Killa Published on March 10,2017

IVV is the second ETF in the space that has managed to garner $100 billion in AUM after SPY.

• JNJ Quick QuoteJNJNo Net Change
• AAPL Quick QuoteAAPLNegative Net Change
• MSFT Quick QuoteMSFTNegative Net Change

Allergan's (AGN) Vraylar sNDA Accepted for Review by FDA

by Zacks Equity Research Published on March 09,2017

Allergan plc (AGN) announced that its supplemental New Drug Application (sNDA) for its schizophrenia capsules Vraylar has been accepted for review by the FDA.

• AZN Quick QuoteAZNPositive Net Change
• AGN Quick QuoteAGNPositive Net Change
• JNJ Quick QuoteJNJNo Net Change
• ALKS Quick QuoteALKSPositive Net Change

The Zacks Analyst Blog Highlights: Johnson & Johnson, Alphabet, Schlumberger, Alibaba and Public Storage

by Zacks Equity Research Published on March 07,2017

The Zacks Analyst Blog Highlights: Johnson & Johnson, Alphabet, Schlumberger, Alibaba and Public Storage

• JNJ Quick QuoteJNJNo Net Change
• GOOGL Quick QuoteGOOGLPositive Net Change
• SLB Quick QuoteSLBPositive Net Change
• BABA Quick QuoteBABAPositive Net Change

J&J Presents Positive Phase III Data on Psoriasis Candidate

by Zacks Equity Research Published on March 06,2017

Johnson & Johnson (JNJ) announced positive data from two phase III studies evaluating its pipeline candidate, guselkumab for the treatment of moderate-to-severe plaque psoriasis.

• JNJ Quick QuoteJNJNo Net Change
• CELG Quick QuoteCELGPositive Net Change
• ABBV Quick QuoteABBVNegative Net Change
• SMMT Quick QuoteSMMTPositive Net Change

Aduro (ADRO) Loss Wider than Expected, Sales Miss in Q4

by Zacks Equity Research Published on March 03,2017

Aduro BioTech, Inc. (ADRO) reported fourth-quarter 2016 loss of 44 cents per share, wider than the Zacks Consensus Estimate of a loss of 38 cents.

• BMY Quick QuoteBMYPositive Net Change
• JNJ Quick QuoteJNJNo Net Change
• MRK Quick QuoteMRKNegative Net Change
• ADRO Quick QuoteADROPositive Net Change

Geron (GERN) Q4 Loss Narrows; Focus Remains on Imetelstat

by Zacks Equity Research Published on March 02,2017

Geron Corporation (GERN) reported a loss of 5 cents per share in the fourth quarter of 2016, flat year over year but narrower than the Zacks Consensus Estimate of a loss of 6 cents.

• JNJ Quick QuoteJNJNo Net Change
• GERN Quick QuoteGERNNegative Net Change
• CELG Quick QuoteCELGPositive Net Change
• SMMT Quick QuoteSMMTPositive Net Change

by Zacks Equity Research Published on February 28,2017

• JNJ Quick QuoteJNJNo Net Change
• PFE Quick QuotePFENegative Net Change
• GSK Quick QuoteGSKPositive Net Change
• AMGN Quick QuoteAMGNNegative Net Change